Orient Bio released its 2026 interim report. First-half operating revenue was 464 million yuan, up 15.2% year on year, but net loss attributable to the parent widened to 222 million yuan, compared with a loss of 163 million yuan in the same period last year. Net loss attributable to the parent after deducting non-recurring items was 238 million yuan, versus a loss of 184 million yuan a year earlier. Net operating cash flow was negative 43.17 million yuan, an improvement of 65% year on year. Second-quarter revenue was 208 million yuan, down 1.5% year on year, and net loss attributable to the parent was 128 million yuan, compared with a loss of 47.65 million yuan a year earlier. As of the end of the second quarter, total assets stood at 6.893 billion yuan, down 3.4% from the end of the previous year, and net assets attributable to the parent were 5.755 billion yuan, down 4%. The company said its main business was driven by routine human medical testing, with overseas sales growth in infectious disease testing reagents boosting overall business growth, while the animal health business is still in the promotion stage.
Zhejiang Orient Gene Biotech Co LtdNet loss widened to 222 million yuan from 163 million yuan, with Q2 loss more than doubling.
